If that was true there would be a lot of insider buying. They are putting in place the pieces for rapid commercialisation should the trials be successful. It also puts pressure on major pharma who no doubt are following developments. They will be in no doubt that the company management can do what they say they will.
Ann: Opthea Appoints John Han, PharmD, as VP Medical Affairs, page-4
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
-0.020(3.77%) |
Mkt cap ! $338.0M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 53.5¢ | 51.0¢ | $373.5K | 711.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 35120 | 50.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 3465 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
51.5¢ |
Change
-0.020 ( 1.90 %) |
||||
| Open | High | Low | Volume | ||
| 51.5¢ | 53.5¢ | 51.0¢ | 118754 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| OPT (ASX) Chart |